British American Tobacco PLC vs Tempus AI — how do they compare? British American Tobacco PLC trades at $58.77 (market cap $124.84B), while Tempus AI trades at $58.33 (market cap $10.54B). The key difference: British American Tobacco PLC is far larger — about 11.8× Tempus AI's market cap, and British American Tobacco PLC pays a 5.74% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| BTI | TEM | |
|---|---|---|
Market Cap | $124.84B | $10.54B |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $66.70 | $103.25 |
52-Week Low | $50.39 | $42.37 |
Enterprise Value | $166.06B | $11.21B |
Dividend Yield | 5.74% | — |
Signals from Pluang's Aura AI — not financial advice
British American Tobacco (BTI) trades at $58.95, down 1.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 30.32% net income margin and attractive valuation at 12.79 P/E ratio. Recent earnings show beats in Q2 and Q4 2025, though Q4 2024 missed expectations. The company is undergoing restructuring with 5,500 job cuts announced in June 2026 to streamline operations and reduce costs.
BTI presents a compelling value opportunity with strong dividend yield and improving earnings trajectory, though facing regulatory headwinds and declining cigarette volumes. The stock's current valuation appears attractive relative to historical levels, supported by robust cash flow generation and strategic pivot toward smoke-free products. Key risks include ongoing regulatory pressures and consumer shift away from traditional tobacco products.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Trailing returns across standard periods
Latest headlines on both assets
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →